MicroRNAs in Cancer

Hamed Mirzaei, Neda Rahimian, Hamid Reza Mirzaei, Javid Sadri Nahand, Michael R. Hamblin

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

6 Citations (Scopus)


The dysrégulation of microRNAs in cancer was first reported in 2002, when a cluster of two microRNAs (miR16 and miR-15) was detected at chromosome 13q14.3, which had been proposed as one of the commonly eliminated genetic regions in chronic lymphocytic leukemia (CLL) patients [1]. The deletion of this miRNA cluster acts (at least partly) by increasing the expression level of the specific target of miR-15/16, which is the anti-apoptotic protein B cell lymphoma 2 (BCL2). It has been found that micro-RNAs can contribute to each cancer hallmark described by Hanahan and Weinberg [2], as well affecting the clinical progression of many cancers at different stages.

Original languageEnglish
Title of host publicationSynthesis Lectures on Biomedical Engineering
PublisherSpringer Nature
Number of pages30
Publication statusPublished - 2022

Publication series

NameSynthesis Lectures on Biomedical Engineering
ISSN (Print)1930-0328
ISSN (Electronic)1930-0336

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biochemistry
  • Biomedical Engineering


Dive into the research topics of 'MicroRNAs in Cancer'. Together they form a unique fingerprint.

Cite this